Image Source: It was a rather quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time.
Zenas BioPharma (ZBIO) staged a rare US biopharma IPO worth $259 million to complete development of its lead product, a bifunctional antibody for autoimmune diseases.
Hangzhou’s TJ Biopharma, which was spun off when I-Mab (IMAB) left China, sold the China rights for its CD73-targeted antibody to Sanofi (SNY) in a $237 million deal.
LongBio Pharma (Suzhou) completed a Series B2 round led by Qiming Venture Partners that raised $14 million for its lead asthma candidate.
Germany’s Bayer (BAYRY) opened its newest life science incubator, Bayer Co.Lab Shanghai, in Shanghai’s Zhangjiang Park.
AstraZeneca Korea (AZN) plans a contest to choose two innovative Korean biohealth companies interested in China for its iCampus innovation hub in Wuxi, China.
More By This Author:
